Cavanagh, Karda
McLean, Luke S. http://orcid.org/0000-0002-5969-1577
Lim, Annette M.
Cardin, Anthony
Levy, Sidney M.
Rischin, Danny
Article History
Received: 19 October 2023
Accepted: 26 February 2024
First Online: 18 March 2024
Declarations
:
: This study was approved by the Human Research Ethics Committee (HREC) of the Peter MacCallum Cancer Centre with a waiver of consent granted.
: NA.
: LSM – honorarium/speakers fees and conference registration support from Sanofi, conference registration and travel support with MSD.AML—uncompensated consultancy for Eisai, salary support from a Peter MacCallum Cancer Centre Discovery Partner Fellowship, and institutional support from Sanofi/Regeneron Pharmaceuticals.DR- Trial steering committees and/or advisory boards (all uncompensated)—MSD, GSK, Regeneron, Sanofi. Institutional trial funding from Merck Sharp & Dohme, Decibel Therapeutics, Bristol-Myers Squibb, GSK, Roche, Regeneron, Kura Oncology, and ALX Oncology.